Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12325426 | 0.82 | KDM4E (0.43) | RAB9ANPC1KDM4EGAASMN1; SMN2 | |
| SCHEMBL16509324 | 0.82 | NPC1 (0.50) | RAB9ANPC1KDM4EGAASMN1; SMN2 | |
| SCHEMBL16509296 | 0.82 | KDM4E (0.50) | RAB9ANPC1KDM4EGAASMN1; SMN2 | |
| SCHEMBL14922007 | 0.81 | KDM4E (0.69) | RAB9ANPC1KDM4EGAASMN1; SMN2 | |
| SCHEMBL14105332 | 0.80 | MAPT (0.49) | RAB9ANPC1KDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL16509206 | 0.79 | RAB9A (0.51) | RAB9ANPC1KDM4EGAASMN1; SMN2 | |
| SCHEMBL16509244 | 0.79 | ADORA3 (0.51) | RAB9ANPC1KDM4EGAASMN1; SMN2 | |
| SCHEMBL16509299 | 0.78 | KDM4E (0.56) | RAB9ANPC1KDM4EGAASMN1; SMN2 | |
| SCHEMBL16509229 | 0.78 | KDM4E (0.47) | RAB9ANPC1KDM4EGAASMN1; SMN2 | |
| SCHEMBL16509197 | 0.75 | GRM5 (0.45) | RAB9ANPC1KDM4EGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | RAB9A 4067/4885NPC1 3055/4885KDM4E 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.